Literature DB >> 31149947

HIV elite control is associated with reduced TRAILshort expression.

Ana C Paim1, Nathan W Cummins1, Sekar Natesampillai1, Enrique Garcia-Rivera2, Nicole Kogan2, Ujjwal Neogi3, Anders Sönnerborg3, Maike Sperk3, Gary D Bren1, Steve Deeks4, Eric Polley5, Andrew D Badley1,6.   

Abstract

OBJECTIVE: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) dependent apoptosis has been implicated in CD4 T-cell death and immunologic control of HIV-1 infection. We have described a splice variant called TRAILshort, which is a dominant negative ligand that antagonizes TRAIL-induced cell death in the context of HIV-1 infection. HIV-1 elite controllers naturally control viral replication for largely unknown reasons. Since enhanced death of infected cells might be responsible, as might occur in situations of low (or inhibited) TRAILshort, we tested whether there was an association between elite controller status and reduced levels of TRAILshort expression.
DESIGN: Cohort study comparing TRAILshort and full length TRAIL expression between HIV-1 elite controllers and viremic progressors from two independent populations.
METHODS: TRAILshort and TRAIL gene expression in peripheral blood mononuclear cells (PBMCs) was determined by RNA-seq. TRAILshort and TRAIL protein expression in plasma was determined by antibody bead array and proximity extension assay respectively.
RESULTS: HIV-1 elite controllers expressed less TRAILshort transcripts in PBMCs (P = 0.002) and less TRAILshort protein in plasma (P < 0.001) than viremic progressors.
CONCLUSION: Reduced TRAILshort expression in PBMCs and plasma is associated with HIV-1 elite controller status.

Entities:  

Year:  2019        PMID: 31149947      PMCID: PMC6873462          DOI: 10.1097/QAD.0000000000002279

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  37 in total

1.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics.

Authors:  Frank Dieterle; Alfred Ross; Götz Schlotterbeck; Hans Senn
Journal:  Anal Chem       Date:  2006-07-01       Impact factor: 6.986

2.  Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV.

Authors:  Stephen A Migueles; Mark Connors
Journal:  JAMA       Date:  2010-07-14       Impact factor: 56.272

3.  Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors.

Authors:  David Shasha; Dan Karel; Olivia Angiuli; Adam Greenblatt; Musie Ghebremichael; Xu Yu; Filippos Porichis; Bruce D Walker
Journal:  J Leukoc Biol       Date:  2016-07-12       Impact factor: 4.962

4.  Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Authors:  David J Schnepple; Brett Shepard; Gary D Bren; Nathan W Cummins; Sekar Natesampillai; Sergey Trushin; Alicia Algeciras-Schimnich; Xue W Meng; Amy M Sainski; Stacey A Rizza; Scott H Kaufmann; Andrew D Badley
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

5.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

Authors:  G Pan; J Ni; Y F Wei; G Yu; R Gentz; V M Dixit
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

Review 6.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

7.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Expression profiles and pathway analysis in HEK 293 T cells overexpressing HIV-1 Tat and nucleocapsid using cDNA microarray.

Authors:  Seong-Eun Park; Min Joo Lee; Moon Hee Yang; Ka Young Ahn; Soo In Jang; Young Ju Suh; Heejoon Myung; Ji Chang You; Jong Hoon Park
Journal:  J Microbiol Biotechnol       Date:  2007-01       Impact factor: 2.351

9.  Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability.

Authors:  Erika Assarsson; Martin Lundberg; Göran Holmquist; Johan Björkesten; Stine Bucht Thorsen; Daniel Ekman; Anna Eriksson; Emma Rennel Dickens; Sandra Ohlsson; Gabriella Edfeldt; Ann-Catrin Andersson; Patrik Lindstedt; Jan Stenvang; Mats Gullberg; Simon Fredriksson
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

10.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

View more
  3 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Authors:  Fatma Aboulnasr; Ashton Krogman; Rondell P Graham; Nathan W Cummins; Anisha Misra; Enrique Garcia-Rivera; Jeff R Anderson; Sekar Natesampillai; Nicole Kogan; Murali Aravamudan; Zilin Nie; Thomas D Y Chung; Richard Buick; Andrew L Feldman; Rebecca L King; Anne J Novak; Stephen M Ansell; Saad Kenderian; Andrew D Badley
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

Review 3.  Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes.

Authors:  Erick De La Torre-Tarazona; Rubén Ayala-Suárez; Francisco Díez-Fuertes; José Alcamí
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.